Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2018 | Transplant trials in myeloma: EMN02 and BMT CTN 0702

Philip McCarthy • 19 Apr 2018
EMN 2018
Multiple Myeloma Bortezomib Dexamethasone Lenalidomide Melphalan Prednisone
BMT CTN 0702 EMN02

Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses two Phase III multiple myeloma (MM) transplantation studies that have been performed: EMN02 (NCT01208766) and BMT CTN 0702 (NCT01109004). Prof. McCarthy highlights how both studies had similar designs, but yielded different results. This video was recorded at the 1st European Myeloma Network Meeting, in Turin, Italy.

More from Philip McCarthy

4:02
Treatment-free intervals: what is best for patients?
Philip McCarthy • 1 Sep 2021
4:22
Future maintenance therapy approaches for multiple myeloma
Philip McCarthy • 1 Sep 2021
5:15
CAR-T for myeloma: where are we now and where are we going?
Philip McCarthy • 1 Sep 2021
10:09
Does maintenance therapy increase overall survival in myeloma?
Andrew Spencer et al. • 13 Sep 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals